This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Fukuoka M et al. (2003) Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237–2246
Kris MG et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149–2158
Shepherd FA et al. (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123–132
Thatcher N et al. (2005) Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366: 1527–1537
Lynch TJ et al. (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129–2139
Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500
Dowell JE and Minna JD (2004) The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy. Nat Clin Pract Oncol 1: 2–3
Tsao MS et al. (2005) Erlotinib in lung cancer—molecular and clinical predictors of outcome. N Engl J Med 353: 133–144
Hirsch FR et al. (2005) Molecular analysis of EGFR gene copy number, EGFR expression and Akt activation status in advanced non-small-cell lung cancer treated with gefitinib or placebo (ISEL trial) [abstract #268a]. In Proceedings of the AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics: 2005 November 14–18; Philadelphia, 124–125
Cappuzzo F et al. (2005) Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97: 643–655
Acknowledgements
Grant support: lung cancer SPORE P50CA70907
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
JE Dowell is on a speakers bureau for Genentech and receives research funding from Genentech. JD Minna receives research support from AstraZeneca and ImClone.
Supplementary information
Supplementary Table 1
EGFR mutation frequencies in specific clinical subsets of non-small-cell lung cancer patients based on a compilation of the published data.
Rights and permissions
About this article
Cite this article
Dowell, J., Minna, J. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer. Nat Rev Clin Oncol 3, 170–171 (2006). https://doi.org/10.1038/ncponc0476
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/ncponc0476
This article is cited by
-
The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer
Cellular & Molecular Biology Letters (2020)
-
ROS-1 rearrangements in non-small cell lung cancer (NSCLC): a new target for a small subset of patients but a giant leap in therapeutics
Current Pulmonology Reports (2016)
-
Salivary gland-type lung carcinomas: an EGFR immunohistochemical, molecular genetic, and mutational analysis study
Modern Pathology (2008)